Michael A. Panzara - 20 May 2022 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Role
Director
Signature
Glenna Mileson, Attorney-in-fact for Michael A. Panzara
Issuer symbol
ATHA
Transactions as of
20 May 2022
Transactions value $
$0
Form type
4
Filing time
27 May 2022, 17:38:52 UTC
Previous filing
06 May 2022
Next filing
27 Jul 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATHA Stock Option (Right to Buy) Award $0 +2.31K $0.00 2.31K 20 May 2022 Common Stock 2.31K $8.93 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option will vest on the earlier of (i) May 20, 2023, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 20, 2022. The option reported was granted pursuant to the terms of the Issuer's outside director compensation policy.